Please Wait.....
Report
Middle East & Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market
Market Report I 2023-10-01 I 165 Pages I Data Bridge Market Research
The Middle East and Africa Acute Respiratory Distress Syndrome (ARDS) treatment market is expected to reach USD 302,177.14 thousand by 2030, from USD 164,931.47 thousand in 2022, growing at the CAGR of 8.3% in the forecast period of 2023 to 2030.
Market Segmentation
Middle East and Africa Acute Respiratory Distress Syndrome (Ards) Treatment Market, By Type (Mechanical Ventilation, Corticosteroids, Antiviral Medication, Extracorporeal Membrane Oxygenation (ECMO), Tocilizumab, and Others), Cause ( Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (South Africa, Saudi Arabia, U.A.E., Israel, Egypt, Kuwait, and rest of Middle East and Africa) - Industry Trends and Forecast to 2030
Overview of Middle East and Africa Acute Respiratory Distress Syndrome (ARDS) Treatment Market Dynamics
Driver
- Increasing prevalence and incidence of acute lung injury in the market
Restraint
- High cost of device and treatment
Opportunity
- Strategic initiatives joined with new product launches by market players
Market Players
Some of the major market players operating in the Middle East and Africa Acute Respiratory Distress Syndrome (ARDS) market are listed below:
- Gilead Sciences, Inc.
- Terumo Medical Corporation
- Getinge AB.
- LivaNova PLC
- Medtronic
- ResMed
- Fisher & Paykel Healthcare Limited.
- Dragerwerk AG & Co. KGaA
- NIPRO
- Fresenius SE & Co. KGaA
- Hamilton Medical
- Pfizer Inc.
- WEINMANN Emergency Medical Technology GmbH + Co. KG
- EUROSETS
- Armstrong Medical
- nice Neotech Medical Systems Pvt. Ltd.
- Besmed Health Business Corp.
TABLE OF CONTENTS
1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 19
1.4 LIMITATIONS 21
1.5 MARKETS COVERED 21
2 MARKET SEGMENTATION 23
2.1 MARKETS COVERED 23
2.2 GEOGRAPHICAL SCOPE 24
2.3 YEARS CONSIDERED FOR THE STUDY 25
2.4 CURRENCY AND PRICING 25
2.5 DBMR TRIPOD DATA VALIDATION MODEL 26
2.6 MULTIVARIATE MODELLING 29
2.7 TYPE LIFELINE CURVE 29
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 30
2.9 DBMR MARKET POSITION GRID 31
2.10 MARKET END USER COVERAGE GRID 32
2.11 VENDOR SHARE ANALYSIS 33
2.12 SECONDARY SOURCES 34
2.13 ASSUMPTIONS 34
3 EXECUTIVE SUMMARY 35
4 PREMIUM INSIGHTS 38
4.1 PESTEL ANALYSIS 39
4.2 PORTER'S FIVE FORCES 40
4.3 INSURANCE REIMBURSEMENT 41
4.3.1 CENTER FOR MEDICARE SERVICES (CMS)-ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 41
4.3.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 41
4.3.3 ABBOTT CODING GUIDE FOR ECMO 42
4.3.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 42
4.3.5 CERN HEALTH INSURANCE SCHEME 43
4.3.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) - (MEDICARE & MEDICAID) 43
4.3.7 AMERICAN HOSPITAL ASSOCIATION 44
4.4 PIPELINE ANALYSIS 45
4.5 PRICING ANALYSIS 47
5 MARKET OVERVIEW 48
5.1 DRIVERS 50
5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 50
5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS TREATMENT 50
5.1.3 RISING RATE OF AIR POLLUTION AND UNHEALTHY LIFESTYLE 51
5.1.4 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 51
5.2 RESTRAINTS 52
5.2.1 COMPLICATIONS ASSOCIATED WITH THE TREATMENT 52
5.2.2 HIGH COST OF DEVICES AND TREATMENT 52
5.3 OPPORTUNITIES 53
5.3.1 RISING HEALTHCARE EXPENDITURE TO IMPROVE TREATMENT FACILITIES 53
5.3.2 STRATEGIC INITIATIVES JOINED WITH NEW PRODUCT LAUNCH BY MARKET PLAYERS 53
5.3.3 IMPROVING AWARENESS REGARDING ARD SYNDROME 54
5.4 CHALLENGES 55
5.4.1 STRINGENT RULES & REGULATIONS 55
5.4.2 MULTIPLE CHALLENGES FACED BY ICU STAFF 56
6 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE 57
6.1 OVERVIEW 58
6.2 MECHANICAL VENTILATION 61
6.2.1 HIGH-FLOW NASAL O2 62
6.2.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 62
6.2.3 CONTINUOUS POSITIVE AIRWAY PRESSURE 62
6.2.4 PRONE POSITION VENTILATION 62
6.2.5 OTHERS 63
6.3 CORTICOSTEROIDS 63
6.3.1 METHYLPREDNISOLONE 64
6.3.2 DEXAMETHASONE 64
6.3.3 OTHERS 64
6.4 ANTIVIRAL MEDICATION 65
6.4.1 RIBAVIRIN 66
6.4.2 OSELTAMIVIR 66
6.4.3 OTHERS 66
6.5 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 66
6.6 TOCILIZUMAB 67
6.7 OTHERS 67
7 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE 68
7.1 OVERVIEW 69
7.2 SEPSIS 72
7.3 INHALATION OF HARMFUL SUBSTANCES 72
7.4 SEVERE PNEUMONIA 73
7.5 OTHERS 73
8 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 74
8.1 OVERVIEW 75
8.2 PARENTERAL 78
8.2.1 INTRAVENOUS 78
8.2.2 INTRAMUSCULAR 78
8.3 ORAL 79
8.4 OTHERS 79
9 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER 80
9.1 OVERVIEW 81
9.2 HOSPITALS 84
9.3 SPECIALTY CLINICS 84
9.4 HOME HEALTHCARE 85
9.5 OTHERS 85
10 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 86
10.1 OVERVIEW 87
10.2 DIRECT TENDER 90
10.3 HOSPITAL PHARMACY 90
10.4 RETAIL PHARMACY 91
10.5 ONLINE PHARMACY 91
11 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION 92
11.1 MIDDLE EAST AND AFRICA 94
11.1.1 SOUTH AFRICA 99
11.1.2 SAUDI ARABIA 104
11.1.3 U.A.E 109
11.1.4 ISRAEL 114
11.1.5 EGYPT 119
11.1.6 KUWAIT 124
11.1.7 REST OF MIDDLE EAST AND AFRICA 129
12 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, COMPANY LANDSCAPE 130
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 130
13 SWOT ANALYSIS 131
14 MIDDLE EAST AND AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT, CPS 132
14.1 GILEAD SCIENCES INC. 132
14.1.1 COMPANY SNAPSHOT 132
14.1.2 REVENUE ANALYSIS 133
14.1.3 COMPANY SHARE ANALYSIS 133
14.1.4 PRODUCT PORTFOLIO 134
14.1.5 RECENT DEVELOPMENT 134
14.2 TERUMO CORPORATION 135
14.2.1 COMPANY SNAPSHOT 135
14.2.2 REVENUE ANALYSIS 135
14.2.3 COMPANY SHARE ANALYSIS 136
14.2.4 PRODUCT PORTFOLIO 136
14.2.5 RECENT DEVELOPMENT 136
14.3 GETINGE 137
14.3.1 COMPANY SNAPSHOT 137
14.3.2 REVENUE ANALYSIS 137
14.3.3 COMPANY SHARE ANALYSIS 138
14.3.4 PRODUCT PORTFOLIO 138
14.3.5 RECENT DEVELOPMENT 138
14.4 LIVANOVA PLC 139
14.4.1 COMPANY SNAPSHOT 139
14.4.2 REVENUE ANALYSIS 139
14.4.3 COMPANY SHARE ANALYSIS 140
14.4.4 PRODUCT PORTFOLIO 140
14.4.5 RECENT DEVELOPMENTS 140
14.5 MEDTRONIC 141
14.5.1 COMPANY SNAPSHOT 141
14.5.2 REVENUE ANALYSIS 141
14.5.3 COMPANY SHARE ANALYSIS 142
14.5.4 PRODUCT PORTFOLIO 142
14.5.5 RECENT DEVELOPMENTS 142
14.6 ARMSTRONG MEDICAL 143
14.6.1 COMPANY SNAPSHOT 143
14.6.2 PRODUCT PORTFOLIO 143
14.6.3 RECENT DEVELOPMENT 143
14.7 BESMED HEALTH BUSINESS CORP. 144
14.7.1 COMPANY SNAPSHOT 144
14.7.2 PRODUCT PORTFOLIO 144
14.7.3 RECENT DEVELOPMENTS 145
14.8 DRAGERWERK AG & CO. KGAA 146
14.8.1 COMPANY SNAPSHOT 146
14.8.2 REVENUE ANALYSIS 146
14.8.3 PRODUCT PORTFOLIO 147
14.8.4 RECENT DEVELOPMENTS 147
14.9 EUROSETS 148
14.9.1 COMPANY SNAPSHOT 148
14.9.2 PRODUCT PORTFOLIO 148
14.9.3 RECENT DEVELOPMENT 148
14.10 FISHER & PAYKEL HEALTHCARE LIMITED 149
14.10.1 COMPANY SNAPSHOT 149
14.10.2 REVENUE ANALYSIS 149
14.10.3 PRODUCT PORTFOLIO 150
14.10.4 RECENT DEVELOPMENTS 150
14.11 FRESENIUS SE & CO. KGAA. 151
14.11.1 COMPANY SNAPSHOT 151
14.11.2 REVENUE ANALYSIS 151
14.11.3 PRODUCT PORTFOLIO 152
14.11.4 RECENT DEVELOPMENT 152
14.12 HAMILTON MEDICAL 153
14.12.1 COMPANY SNAPSHOT 153
14.12.2 PRODUCT PORTFOLIO 153
14.12.3 RECENT DEVELOPMENT 153
14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD. 154
14.13.1 COMPANY SNAPSHOT 154
14.13.2 PRODUCT PORTFOLIO 154
14.13.3 RECENT DEVELOPMENT 154
14.14 NIPRO 155
14.14.1 COMPANY SNAPSHOT 155
14.14.2 REVENUE ANALYSIS 155
14.14.3 PRODUCT PORTFOLIO 156
14.14.4 RECENT DEVELOPMENT 156
14.15 PFIZER INC. 157
14.15.1 COMPANY SNAPSHOT 157
14.15.2 REVENUE ANALYSIS 157
14.15.3 PRODUCT PORTFOLIO 158
14.15.4 RECENT DEVELOPMENT 158
14.16 RESMED 159
14.16.1 COMPANY SNAPSHOT 159
14.16.2 REVENUE ANALYSIS 159
14.16.3 PRODUCT PORTFOLIO 160
14.16.4 RECENT DEVELOPMENT 160
14.17 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 161
14.17.1 COMPANY SNAPSHOT 161
14.17.2 PRODUCT PORTFOLIO 161
14.17.3 RECENT DEVELOPMENT 161
15 QUESTIONNAIRE 162
16 RELATED REPORTS 165
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security